MR-Guided Radiotherapy for Prostate Cancer

Boris R Tocco; Amar U Kishan; Ting Martin Ma; Linda G W Kerkmeijer; Alison C Tree

doi:10.3389/fonc.2020.616291

MR-Guided Radiotherapy for Prostate Cancer

Boris R Tocco, Amar U Kishan, Ting Martin Ma, Linda G W Kerkmeijer, Alison C Tree

Research output: Contribution to journal › Review article › peer-review

Abstract

External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.

Original language	English
Article number	616291
Pages (from-to)	616291
Journal	Frontiers in oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.616291
Publication status	Published - 9 Dec 2020
Externally published	Yes

Keywords

image-guided radiotherapy
MR-guided radiotherapy
MR-linac
online adaptive radiotherapy
prostate cancer

Access to Document

10.3389/fonc.2020.616291

Cite this

@article{a8581544a6e646d08655ed20328b9974,

title = "MR-Guided Radiotherapy for Prostate Cancer",

abstract = "External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.",

keywords = "image-guided radiotherapy, MR-guided radiotherapy, MR-linac, online adaptive radiotherapy, prostate cancer",

author = "Tocco, {Boris R} and Kishan, {Amar U} and Ma, {Ting Martin} and Kerkmeijer, {Linda G W} and Tree, {Alison C}",

note = "Funding Information: This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden Hospital and the Institute of Cancer Research, London. The views expressed are those of the authors (BT and AT) and not necessarily those of the NIHR or the Department of Health and Social Care. AK gratefully acknowledges support from the American Society for Radiation Oncology and the Prostate Cancer Foundation. We would like to thank Minsong Cao, PhD, for assistance with Figure 2. AT gratefully acknowledges the support of the Medical Research Council and the Rosetrees Trust. Funding Information: This work was supported by Cancer Research UK grant C33589/A28284. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Tocco, Kishan, Ma, Kerkmeijer and Tree.",

year = "2020",

month = dec,

day = "9",

doi = "10.3389/fonc.2020.616291",

language = "English",

volume = "10",

pages = "616291",

journal = "Frontiers in oncology",

issn = "2234-943X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - MR-Guided Radiotherapy for Prostate Cancer

AU - Tocco, Boris R

AU - Kishan, Amar U

AU - Ma, Ting Martin

AU - Kerkmeijer, Linda G W

AU - Tree, Alison C

N1 - Funding Information: This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden Hospital and the Institute of Cancer Research, London. The views expressed are those of the authors (BT and AT) and not necessarily those of the NIHR or the Department of Health and Social Care. AK gratefully acknowledges support from the American Society for Radiation Oncology and the Prostate Cancer Foundation. We would like to thank Minsong Cao, PhD, for assistance with Figure 2. AT gratefully acknowledges the support of the Medical Research Council and the Rosetrees Trust. Funding Information: This work was supported by Cancer Research UK grant C33589/A28284. Publisher Copyright: © Copyright © 2020 Tocco, Kishan, Ma, Kerkmeijer and Tree.

PY - 2020/12/9

Y1 - 2020/12/9

N2 - External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.

AB - External beam radiotherapy remains the primary treatment modality for localized prostate cancer. The radiobiology of prostate carcinoma lends itself to hypofractionation, with recent studies showing good outcomes with shorter treatment schedules. However, the ability to accurately deliver hypofractionated treatment is limited by current image-guided techniques. Magnetic resonance imaging is the main diagnostic tool for localized prostate cancer and its use in the therapeutic setting offers anatomical information to improve organ delineation. MR-guided radiotherapy, with daily re-planning, has shown early promise in the accurate delivery of radiotherapy. In this article, we discuss the shortcomings of current image-guidance strategies and the potential benefits and limitations of MR-guided treatment for prostate cancer. We also recount present experiences of MR-linac workflow and the opportunities afforded by this technology.

KW - image-guided radiotherapy

KW - MR-guided radiotherapy

KW - MR-linac

KW - online adaptive radiotherapy

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85098218028&partnerID=8YFLogxK

U2 - 10.3389/fonc.2020.616291

DO - 10.3389/fonc.2020.616291

M3 - Review article

C2 - 33363041

SN - 2234-943X

VL - 10

SP - 616291

JO - Frontiers in oncology

JF - Frontiers in oncology

M1 - 616291

ER -

MR-Guided Radiotherapy for Prostate Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this